The American Journal of Surgery
Volume 199, Issue 1, Supplement , Pages S3-S10, January 2010

Risk assessment as a guide for the prevention of the many faces of venous thromboembolism

  • Joseph A. Caprini, M.D.

      Affiliations

    • Corresponding Author InformationCorresponding author: Tel.: +1-847-663-8050; fax: +1-847-663-8054

University of Chicago, Pritzker School of Medicine, Chicago, IL, USA

Received 23 July 2009; received in revised form 1 October 2009

Abstract 

Background

Approximately 900,000 cases of deep vein thrombosis and pulmonary embolism occur annually in the United States, and one-third lead to the patient's death. A variety of surgical factors contribute to Virchow's triad of venous stasis, vascular injury, and hypercoagulability, including intraoperative venous distension and microvascular endothelial damage. Patients also may have individual risk factors such as a history of thromboembolism, cancer, advanced age, or a genetic trait linked to hypercoagulation. This article discusses recent trends in the development and validation of venous thromboembolism risk scores, including the results of a large validation study.

Data sources

A Medline literature search was performed to identify original studies.

Conclusions

Venous thromboembolism risk scores have been developed for groups of patients based on a few broad risk categories, but a more accurate, individualized risk score can be obtained using a recently validated risk scoring system, which can be used to determine the type and length of prophylaxis to administer. Further studies are under way to refine this system.

Keywords: Venous thromboembolism, Risk assessment, Prophylaxis, Postthrombotic syndrome, Deep vein thrombosis, Pulmonary embolism

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Caprini is on the speakers' bureau for Covidien and sanofi-aventis; on the advisory board for ConvaTec, Covidien, Eisai, and sanofi-aventis; and a consultant for ConvaTec, Covidien, and sanofi-aventis.

PII: S0002-9610(09)00638-2

doi:10.1016/j.amjsurg.2009.10.006

The American Journal of Surgery
Volume 199, Issue 1, Supplement , Pages S3-S10, January 2010